The prince and the pauper. A tale of anticancer targeted agents.
The prince and the pauper. A tale of anticancer targeted agents.
复制标题
DOI：
10.1186/1476-4598-7-82
复制
发表时间：
2008-10-23
期刊：
影响因子：
37.3
通讯作者：
Candelaria M
中科院分区：
文献类型：
--
作者：
Dueñas-González A;García-López P;Herrera LA;Medina-Franco JL;González-Fierro A;Candelaria M
癌症发病率将以惊人的速度增加，从2000年全球新增病例1000万增加到2020年的1500万。关于癌症的药物治疗，我们目前正处于两个治疗时代的中间阶段。所谓前基因组治疗，指的是传统的抗癌药物，主要是细胞毒性药物类型，而后基因组时代的药物则指的是基于合理设计的药物。尽管这种新的药物发现方法有成功的例子，但大多数靶向特异性药物仅在症状控制和/或生存方面取得了很小的进展，而其他药物在临床测试中一直失败。然而，这些代理商有一个共同的特点：-成本高-。这是预料之中的，因为药物发现和开发通常是在商业领域而不是学术领域进行的。鉴于与治疗药物发现相关的极高成本和风险，任何一个公共部门研究小组都不太可能看到一种新型化学“探针”成为“药物”。另一种药物开发策略是开发已被批准用于治疗非癌症疾病且其癌症靶点已被发现的既定药物。该策略也称为药物重新定位、药物再利用或适应症转换。尽管传统上大型制药公司不太可能开发这些药物，因为它们的商业价值有限，但目前试图提高生产率的生物制药公司正在寻求药物的重新定位。越来越多的公司正在扫描现有药典以寻找重新定位候选药物，并且重新定位成功案例的数量正在增加。在这里，我们提供了一些值得注意的已知药物的例子，这些药物的潜在抗癌活性已被强调，以鼓励对这些已知药物进行进一步研究，以此作为利用更有限的公共部门资源促进其转化为临床试验的手段。如果这些药物类型最终有效，那么癌症患者可能更能负担得起它们；因此，它们对降低全球癌症死亡率的贡献将会更大。
Cancer rates are set to increase at an alarming rate, from 10 million new cases globally in 2000 to 15 million in 2020. Regarding the pharmacological treatment of cancer, we currently are in the interphase of two treatment eras. The so-called pregenomic therapy which names the traditional cancer drugs, mainly cytotoxic drug types, and post-genomic era-type drugs referring to rationally-based designed. Although there are successful examples of this newer drug discovery approach, most target-specific agents only provide small gains in symptom control and/or survival, whereas others have consistently failed in the clinical testing. There is however, a characteristic shared by these agents: -their high cost-. This is expected as drug discovery and development is generally carried out within the commercial rather than the academic realm. Given the extraordinarily high therapeutic drug discovery-associated costs and risks, it is highly unlikely that any single public-sector research group will see a novel chemical "probe" become a "drug". An alternative drug development strategy is the exploitation of established drugs that have already been approved for treatment of non-cancerous diseases and whose cancer target has already been discovered. This strategy is also denominated drug repositioning, drug repurposing, or indication switch. Although traditionally development of these drugs was unlikely to be pursued by Big Pharma due to their limited commercial value, biopharmaceutical companies attempting to increase productivity at present are pursuing drug repositioning. More and more companies are scanning the existing pharmacopoeia for repositioning candidates, and the number of repositioning success stories is increasing. Here we provide noteworthy examples of known drugs whose potential anticancer activities have been highlighted, to encourage further research on these known drugs as a means to foster their translation into clinical trials utilizing the more limited public-sector resources. If these drug types eventually result in being effective, it follows that they could be much more affordable for patients with cancer; therefore, their contribution in terms of reducing cancer mortality at the global level would be greater.
登录
查看更多内容
影响因子：
3.1
作者：
Alsdorf, Rachel;Wyszynski, Diego F
通讯作者：
Wyszynski, Diego F
影响因子：
3.7
作者：
Andreoli, Christopher M.;Miller, Joan W.
通讯作者：
Miller, Joan W.
影响因子：
37.8
作者：
Arita, Y;Kihara, S;Matsuzawa, Y
通讯作者：
Matsuzawa, Y
DOI：
10.1016/0731-7085(91)80200-s
发表时间：
1991-01-01
影响因子：
3.4
作者：
BALBI, A;SOTTOFATTORI, E;SANNITA, WG
通讯作者：
SANNITA, WG
影响因子：
168.9
作者：
Baigent, C;Keech, A;Simes, J
通讯作者：
Simes, J